Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance

Uncategorized
November 1, 2022
img: Featured

INGREZZA ® (valbenazine) Third Quarter Net Product Sales of $376 Million INGREZZA ® (valbenazine) 2022 Net Product Sales Guidance Raised to $1.4 – $1.425 Billion Supplemental New Drug Application (sNDA) of Valbenazine For the Treatment of Chorea in Patients with Huntington Disease Submitted to the

Uncategorized